New sickle cell Drug's heart effects tested in healthy volunteers
NCT ID NCT07023029
Summary
This early-stage study tested whether a potential new medicine for sickle cell disease, called etavopivat, affects the heart's electrical activity. Researchers gave the drug at different doses to 33 healthy volunteers to check for safety, particularly looking at heart rhythm. The study compared etavopivat to a placebo and an approved antibiotic to see if it caused any concerning changes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
PAREXEL Intl - EPCU-Baltimore
Baltimore, Maryland, 21225, United States
Conditions
Explore the condition pages connected to this study.